In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Researchers at the University of Oxford and their collaborators, including the Serum Institute of India, have developed an innovative method to identify falsified vaccines without opening the vaccine ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

High vaccine wastage and low vaccination and booster rates marred the government’s P74.68-million COVID-19 National ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of its ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain ...

We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...